Skip to main content

Table 3 Description of adequacy of therapy **.

From: Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

FACTOR CASE FATALITY WITH FACTOR CASE FATALITY WITHOUT FACTOR RELATIVE RISK (95% CI) P-VALUE
Adequate by t = 0 1/11 (9%) 15/68 (22%) 0.41 (0.06-2.81) NS
Adequate by t = 8 hours 6/22 (27%) 10/57(18%) 1.55 (0.64-3.76) 0.09
Adequate by t = 24 hours 7/28 (25%) 9/51 (18%) 1.42 (0.59-3.39) 0.10
Adequate by t = 48 hours 9/42 (21%) 7/37 (18%) 1.13 (0.47-2.74) NS
Adequate at t > 48 hours 3/33 (9%) 13/46 (28%) 0.32 (0.10-1.04) NS
Never received adequate therapy 4/4 (100%) 12/75 (16%) 6.25 (3.72-10.5) 0.01
First Adequate Antibiotic Choice     
Beta-lactam/Beta-lactamase inhibitor combination 6/28 (21%) 10/51 (20%) 1.09 (0.44-2.69) NS
Carbapenem 4/30 (13%) 12/49 (24%) 0.54 (0.19-1.53) NS
Fluoroquinolone 1/4 (25%) 15/75 (20%) 1.25 (0.22-7.24) NS
Aminoglycoside 1/10 (10%) 15/69 (22%) 0.46 (0.07-3.11) NS
Sulfa 1/3 (33%) 15/76 (20%) 1.69 (0.32-8.91) NS
  1. ** Adequate therapy was defined by the receipt of a standard parenteral dose of an antimicrobial to which the organism was fully susceptible in vitro based on Clinical and Laboratory Standards Institute (CLSI) breakpoints or a standard oral dose of an antimicrobial with high bioavailability by this route, to which the organism was also fully susceptible.